-
Sector Analysis
Glioblastoma Multiforme (GBM) – Cell and Gene Therapies 15-Market Assessment and Sales Forecast to 2031
Glioblastoma Multiforme Market Report Overview The Glioblastoma Multiforme market value for the 15 markets (15M) was $630 million in 2021. This included both CGTs and established/traditional GBM therapies. The Glioblastoma Multiforme market research report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and pipeline therapies with established mechanisms of action and cell therapies by class, including early to late clinical-stage pipeline products, with a launch date assessment by the market for...
-
Sector Analysis
Glioblastoma Multiforme: Global Drug Forecast and Market Analysis to 2030
Glioblastoma multiforme (GBM) is now defined by the WHO 2021 as a diffuse astrocytic glioma with no mutations in IDH genes or histone H3 genes. It is the most common primary brain tumor in humans. Like other astrocytomas, GBM originates from astrocytes, a type of glial cells that are non-neuronal and function to provide structural and biochemical support to the brain's neuronal network. GBM continues to be a disease with some of the highest unmet needs in oncology, with patients...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.